# [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

> **NCT07238322** · — · COMPLETED · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 253 (actual)

## Conditions studied

- Retrospective Study
- Glioma
- Brain Neoplasms

## Interventions

- **DIAGNOSTIC_TEST:** 18F(FET)PET

## Key facts

- **NCT ID:** NCT07238322
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-22
- **Primary completion:** 2026-01-23
- **Final completion:** 2026-01-23
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07238322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07238322, "[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07238322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*